Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...343344345346347348349350351352353...10671068»
  • ||||||||||  dexamethasone / Generic mfg., cisplatin / Generic mfg., olanzapine / Generic mfg.
    Journal:  Olanzapine 5 mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy. (Pubmed Central) -  Apr 1, 2022   
    Regarding the adverse effects, the incidence of somnolence in the 10 mg group (58.6%) was significantly higher than that in the 5 mg group (41.3%) (P = 0.034), while constipation (20.0% vs. 24.0%, P = 0.554) and hiccups (9.3% vs. 10.6%, P = 0.785) rates were comparable in two groups. Patients receiving olanzapine plus standard antiemetic therapy has excellent antiemetic effect in NPC patients receiving cisplatin-based concurrent chemoradiotherapy, and patients with olanzapine 5 mg have a similar antiemetic effect and lower adverse effects compared with those with olanzapine 10 mg.
  • ||||||||||  hydrocortisone / Generic mfg., cytarabine / Generic mfg.
    Trial termination:  Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL (clinicaltrials.gov) -  Apr 1, 2022   
    P1,  N=3, Terminated, 
    Patients receiving olanzapine plus standard antiemetic therapy has excellent antiemetic effect in NPC patients receiving cisplatin-based concurrent chemoradiotherapy, and patients with olanzapine 5 mg have a similar antiemetic effect and lower adverse effects compared with those with olanzapine 10 mg. Completed --> Terminated; drug supply
  • ||||||||||  SOMther (lutetium-177 DOTA satoreotide) / Ariceum Therap
    Trial completion date, Trial termination, Trial primary completion date:  Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs (clinicaltrials.gov) -  Mar 31, 2022   
    P1/2,  N=40, Terminated, 
    Trial completion date: Jan 2023 --> Feb 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2023 --> Feb 2022; Terminated (Due to small number of ongoing patients. Patients ongoing at time of termination could choose to join study D-FR-01072-004 for long term follow-up.
  • ||||||||||  Empliciti (elotuzumab) / AbbVie, BMS
    Trial termination, Combination therapy:  Combination Study for High Risk Multiple Myeloma Patients (clinicaltrials.gov) -  Mar 31, 2022   
    P2,  N=13, Terminated, 
    Patients ongoing at time of termination could choose to join study D-FR-01072-004 for long term follow-up. Active, not recruiting --> Terminated; The study was terminated early by Funding Sponsor due to low enrollment.
  • ||||||||||  diphenhydramine / Generic mfg., hydrocortisone / Generic mfg.
    Retrospective data, Journal:  Echis coloratus envenomation in children: a retrospective case series. (Pubmed Central) -  Mar 31, 2022   
    No further adverse reactions were observed. In children, Echis coloratus antivenom appeared to be effective and safe for the treatment of systemic and progressive local manifestations of envenomation by Echis coloratus.
  • ||||||||||  hydrocortisone / Generic mfg.
    Retrospective data, Review:  Effect of adjunctive vitamin C, glucocorticoids, and vitamin B1 on longer-term mortality in adults with sepsis or septic shock: a systematic review and a component network meta-analysis. (Pubmed Central) -  Mar 31, 2022   
    Multiple reviewers independently selected randomized controlled trials (RCTs) comparing very-high-dose vitamin C (≥ 12 g/day), high-dose vitamin C (< 12, ≥ 6 g/day), vitamin C (< 6 g/day), glucocorticoid (< 400 mg/day of hydrocortisone), vitamin B1, combinations of these drugs, and placebo/usual care...Adding glucocorticoid to other treatments shortened duration of vasopressor therapy (incremental mean difference, - 29.8 h [95% CI - 44.1 to - 15.5]) and ICU stay (incremental mean difference, - 1.3 days [95% CI - 2.2 to - 0.3]). Metabolic resuscitation with vitamin C, glucocorticoids, vitamin B1, or combinations of these drugs was not significantly associated with a decrease in longer-term mortality.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Anti-inflammatory Dimeric Benzophenones from an Endophytic Pleosporales Species. (Pubmed Central) -  Mar 31, 2022   
    This is the first report of a benzophenone dimer connection via a C bridge from natural sources. An anti-inflammatory assay indicated that the dimeric benzophenones (1-3) inhibited lipopolysaccharide-induced NO production in RAW 264.7 cells, with half-maximal inhibitory concentration (IC) values ranging from 8.8 to 18.1 μM, being more potent than the positive control, dexamethasone (IC = 22.2 μM).
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Retrospective data, Journal:  Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID-19 Pneumonia: A Single-Center Retrospective Study. (Pubmed Central) -  Mar 31, 2022   
    An anti-inflammatory assay indicated that the dimeric benzophenones (1-3) inhibited lipopolysaccharide-induced NO production in RAW 264.7 cells, with half-maximal inhibitory concentration (IC) values ranging from 8.8 to 18.1 μM, being more potent than the positive control, dexamethasone (IC = 22.2 μM). Early initiation of TCZ seems beneficial and safe in patients with moderate to critical COVID-19 pneumonia.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia. (Pubmed Central) -  Mar 31, 2022   
    P3
    Survival without moderate or severe neurodevelopmental impairment did not differ substantially between the two groups. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01353313.).
  • ||||||||||  Nasonex (mometasone furoate nasal spray) / Merck (MSD)
    New trial:  Mometasone Furoate Nasal Spray in Italian Children (clinicaltrials.gov) -  Mar 31, 2022   
    P=N/A,  N=80, Completed, 
  • ||||||||||  Omblastys (131I-omburtamab) - Y / mAbs Therap
    Enrollment open:  131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (clinicaltrials.gov) -  Mar 31, 2022   
    P2,  N=62, Recruiting, 
    (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01353313.). Active, not recruiting --> Recruiting
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Retrospective data, Journal:  Role of pulse methylprednisolone in epileptic encephalopathy: A retrospective observational analysis. (Pubmed Central) -  Mar 30, 2022   
    Adjunct pulse doses of IVMP are safe, well-tolerated, and effective in reducing seizures and improving global outcomes in children with idiopathic EEs, West syndrome, normal neuroimaging, and myoclonic jerks. Seizure freedom might be delayed in a subset of these patients, hence duration of therapy beyond 3 months may be warranted.
  • ||||||||||  Veramyst (fluticasone furoate nasal spray) / GSK
    Journal:  Nasal Polyposis and Its Association with Cardiac Functions. (Pubmed Central) -  Mar 30, 2022   
    The results of these studies are required before definitive conclusions can be made regarding the impact of this novel treatment strategy on the morbidity and mortality of patients with sepsis. Nasal polyp affects cardiac functions, and this needs further evaluation and research through studies on large samples.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Stress-induced glucocorticoids alter the Leydig cells' timing and steroidogenesis-related systems. (Pubmed Central) -  Mar 30, 2022   
    The principal-component-analysis (PCA) displayed an absence of significant differences between treatments especially on Per1 and Rev-erba, the findings confirmed by the in vivo blockade of the testicular glucocorticoid receptor (GR) during stress and ex vivo treatment of the Leydig cells with hydrocortisone and GR-blocker. In summary, stressful stimuli can entrain the clock in the Leydig cells through glucocorticoid-mediated communication.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Pulmonary embolism after dexamethasone treatment for COVID-19: a case report. (Pubmed Central) -  Mar 30, 2022   
    In this critical clinical period, the patient's deteriorating condition may be overlooked because of the masking effects of dexamethasone treatment on fever and other clinical conditions and laboratory changes. Clinicians should follow-up coagulation markers carefully and contrast-enhanced computed tomography is useful for detecting coagulation; and, if PE occurs, therapeutic heparin administration is essential because emboli can also generate cytokines.
  • ||||||||||  methylprednisolone oral / Generic mfg., azithromycin / Generic mfg.
    Journal:  Macrolides as a possible cause of hearing loss in childhood (Pubmed Central) -  Mar 30, 2022   
    Ototoxicity is a cause that must be considered in the case of SHL in childhood. A multidisciplinary approach will allow effective treatment in these patients, in which early management with an adequate hearing aid will restore hearing and achieve adequate speech development and linguistic competence.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Hydrocortisone to Prevent Bronchopulmonary Dysplasia - Not a Silver Bullet. (Pubmed Central) -  Mar 30, 2022   
    A multidisciplinary approach will allow effective treatment in these patients, in which early management with an adequate hearing aid will restore hearing and achieve adequate speech development and linguistic competence. No abstract available
  • ||||||||||  betamethasone / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Pharmacokinetics (PK) and Modeling of Betamethasone Therapy in Threatened Preterm Birth (clinicaltrials.gov) -  Mar 29, 2022   
    P=N/A,  N=210, Completed, 
    Future studies are focusing on the addition of a programmed death-ligand 1 (PD-L1) inhibitor and hematopoietic stem cell transplant (HSCT). Recruiting --> Completed | Trial completion date: May 2021 --> Mar 2022 | Trial primary completion date: May 2021 --> Mar 2022
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Investigation of human adipose-derived stem-cell behavior using a cell-instructive polydopamine-coated gelatin-alginate hydrogel. (Pubmed Central) -  Mar 29, 2022   
    The pDA treatment efficiently retained the drug and the peptide compared to the untreated hydrogel and proved to be effective in controlling the morphology, cell area, and osteogenic differentiation of hASCs. Overall, the findings of this study confirm the efficacy of pDA treatment as a valuable strategy to modulate the biological properties of biocompatible Gel-Alg hydrogels and further extend their value in regenerative medicine.